Table 3.
Outcomes according to surveillance group
| MG group n = 94 | MG + A-MRI group n = 104, breast findings only | MG + A-MRI group n = 104, including extramammary findings | ||
|---|---|---|---|---|
| Outcome | P value** | |||
| False negativea | 3 | 0 | 0 | - |
| True negative | 87 | 77 | 74 | - |
| False positiveb | 3 | 22 | 24 | - |
| True positive | 1 | 5 | 6 | - |
| Recall rate | 4.3% (4/94) | 26% (27/104) | 28.9% (30/104) | < 0.0001 |
| Biopsy rate | 2.1% (2/94) | 19.2% (20/104) | 21.2% (22/104) | 0.0001 |
| CDR per 1000 | 10.6 | 48.1 | 58 | 0.1249 |
| Cancers diagnosed per 1000 including follow-up | 42.6 | 48.1 | 58 | 0.8522 |
| PPV2 (biopsies recommended) | 50% (1/2) | 25% (5/20) | 27.3% (6/22) | 0.4805 |
| PPV3 (biopsies performed) | 50% (1/2) | 25% (5/20) | 27.3% (6/22) | 0.4805 |
| Sensitivity | 25% (1/4) | 100% (5/5) | 100% (6/6) | 0.048 |
| Specificity | 96.7% (87/90) | 77.8% (77/99) | 75.5% (74/98) | 0.0001 |
aFalse negatives includes breast cancers found at follow-up
bIn the MG plus A-MRI surveillance group, 1 false positive was found with mammography and 2 false positives were found with both MG and A-MRI. All other false positives were found with A-MRI only
**p values were obtained comparing the MG group with the MG + A-MRI surveillance groups for intramammary findings only